Blueprint Medicines Corp reports results for the quarter ended in September - Earnings Summary

Blueprint Medicines

26/10/2023 14:32

* Blueprint Medicines Corp  BPMC.OQ  reported a quarterly
adjusted
loss of $2.20​​ per share for the quarter ended in September.
The mean expectation of eighteen analysts for the quarter was
for a loss of $2.37 per share.
    * Revenue fell 14.3% to $56.57 million from a year ago;
analysts
expected $50.40 million. 
    * Blueprint Medicines Corp's reported EPS for the quarter
was a
loss of $2.20​.
    * The mean earnings estimate of analysts had risen by
about 5% in
the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Blueprint Medicines Corp shares had fallen by 12.5% this
quarter and gained 0.3% so far this year.
    * The company reported a quarterly loss of $133.71 million.
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $82.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
October 26 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -2.37          -2.20          Beat
 Jun. 30 2023      -2.54          -2.19          Beat
 Mar. 31 2023      -2.67          -2.15          Beat
 Dec. 31 2022      -2.65          -2.65          Met